

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)



(10) International Publication Number
WO 2021/127525 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) *C07K 16/36* (2006.01)
A61K 39/395 (2006.01) *C12N 1/15* (2006.01)
A61P 7/02 (2006.01) *C12N 1/19* (2006.01)
A61P 7/04 (2006.01)

MA 02142 (US). **GLASSPOOL, Royston, J.**; c/o Anthos Therapeutics, Inc., 55 Cambridge Parkway, Cambridge, MA 02142 (US). **FREEMAN, Jonathan, E.**; c/o Anthos Therapeutics, Inc., 55 Cambridge Parkway, Cambridge, MA 02142 (US).

(21) International Application Number:

PCT/US2020/066151

(74) Agent: **ASHRAF, Shovon** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7Th Fl, Boston, MA 02210 (US).

(22) International Filing Date:

18 December 2020 (18.12.2020)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/951,887 20 December 2019 (20.12.2019) US


(71) Applicant: **ANTHOS THERAPEUTICS, INC.** [US/US]; 55 Cambridge Parkway, Cambridge, MA 02142 (US).

(72) Inventors: **FREEDHOLM, Debra, A.**; c/o Anthos Therapeutics, Inc., 55 Cambridge Parkway, Cambridge, MA 02142 (US). **BLOOMFIELD, Daniel, M.**; c/o Anthos Therapeutics, Inc., 55 Cambridge Parkway, Cambridge,

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH,

(54) Title: PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR FACTOR XI/XIA ANTIBODIES

FIG. 2B



(57) Abstract: This disclosure relates to pharmaceutical formulations of anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies, or antigen-binding fragments thereof. Also provided are dosage regimens for such antibodies or antigen-binding fragments thereof, pharmaceutical formulations comprising the same, and pharmaceutical formulations for use in the treatment of thromboembolic disorders or related conditions.

[Continued on next page]

WO 2021/127525 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))